Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Position in Innoviva, Inc. $INVA

Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Innoviva, Inc. (NASDAQ:INVA) by 838.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 115,503 shares of the biotechnology company’s stock after buying an additional 103,200 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.18% of Innoviva worth $2,108,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of INVA. Royal Bank of Canada boosted its stake in shares of Innoviva by 81.1% during the 1st quarter. Royal Bank of Canada now owns 21,530 shares of the biotechnology company’s stock worth $389,000 after acquiring an additional 9,639 shares in the last quarter. AQR Capital Management LLC boosted its position in Innoviva by 17.8% during the first quarter. AQR Capital Management LLC now owns 167,456 shares of the biotechnology company’s stock worth $3,036,000 after purchasing an additional 25,317 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Innoviva by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,882 shares of the biotechnology company’s stock valued at $596,000 after purchasing an additional 1,392 shares during the period. NewEdge Advisors LLC acquired a new stake in Innoviva in the first quarter valued at approximately $243,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Innoviva by 21.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 171,116 shares of the biotechnology company’s stock valued at $3,102,000 after buying an additional 30,792 shares in the last quarter. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Stock Performance

NASDAQ:INVA opened at $19.75 on Friday. The company has a market cap of $1.48 billion, a P/E ratio of 14.42 and a beta of 0.44. Innoviva, Inc. has a twelve month low of $16.52 and a twelve month high of $22.76. The company’s 50-day moving average price is $20.16 and its 200-day moving average price is $19.57. The company has a current ratio of 14.12, a quick ratio of 13.33 and a debt-to-equity ratio of 0.25.

Innoviva (NASDAQ:INVA) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.62. Innoviva had a net margin of 32.78% and a return on equity of 28.17%. The company had revenue of $107.80 million during the quarter, compared to the consensus estimate of $91.31 million. On average, sell-side analysts forecast that Innoviva, Inc. will post 0.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on INVA. Wall Street Zen upgraded Innoviva from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 25th. Cantor Fitzgerald upped their price objective on shares of Innoviva from $29.00 to $31.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. HC Wainwright increased their price objective on shares of Innoviva from $45.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Weiss Ratings reiterated a “buy (b)” rating on shares of Innoviva in a research report on Monday, December 29th. Finally, Zacks Research downgraded shares of Innoviva from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $38.80.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin?out transaction in 2014, separating the royalty assets from a research?based biopharmaceutical enterprise to create a specialized investment vehicle.